HealthcareLarge capRs 30,059 crRs 119.7 cr traded a day
Close on 2026-08-21
23,301.00
−1.13%
52-week range97% of the way up
11,555.0023,661.00
Market cap
30,059 cr
P/E (TTM)
60.4×
industry 44×
EPS (TTM)
385.85
Revenue YoY
+119.2%
Q1 FY27
Profit YoY
+962.4%
Net margin
23.0%
+18.3pt vs a year ago
Growth trend
-17.2pt
vs last quarter’s YoY
1 month
+26.4%
Below 52w high
1.5%
RSI (14)
73
overbought
Daily swing
3.9%
average true range
Volume
0.3×
vs 20-day average
Traded
Rs 120 cr
median day
Close200-day averageMaterial filing
260 sessions · hover for the filing behind a move
1 week
−0.08%
1 month
+26.42%
3 months
+36.49%
6 months
+76.47%
1 year
+69.73%
The read
written from the numbers on this page
The evidence leans constructive8 supporting, 2 against, 1 worth knowing
Supporting
trading 46% above its 200-day average
sitting at 97% of its 52-week range, with little overhead supply from trapped buyers
up 70% over twelve months
matches stretched far above trend, which has beaten the market by +0.82 points over 20 sessions across 27,715 past signals
3 of the scans it matches have a positive measured record
6 independent kinds of evidence agree today, which is uncommon
revenue grew 119% year on year in the quarter ending 2026-06-30
net margin has widened from 18.8% to 23.0% across four quarters
Against
1 of the scans it matches has historically underperformed the market
priced at 60× earnings against an industry median of 44× — 37% above its peers
Worth knowing
RSI at 73 is stretched; strong stocks stay stretched for a long time, so this is a note on entry timing, not on direction
What would change this read: a close below 16,001, its 200-day average; a failure to hold the top of its 52-week range.
Assembled automatically from the figures on this page — the scans matched, their measured record, the filed financials, the derivatives positioning and the peer comparison. It is not a recommendation, no one has spoken to the company, and every claim above can be checked against a number further down this page.
What is working, what is not
read from the filings, with the figure behind every line
Working3
Revenue +119.2% year on year, Rs 293 cr to Rs 642 cr.
+119.2%Rs 293 crRs 642 cr
Net profit +962.4% year on year, Rs 14 cr to Rs 148 cr.
+962.4%Rs 14 crRs 148 cr
Profit grew faster than revenue, +962.4% against +119.2%.
+962.4%+119.2%
Needs watching
Nothing in the filings stands out either way.
Every figure here is computed from the company’s own filings. The wording is generated directly from the figures.
How it has performed
price return over each window, measured against zero
What the scans say today
12 of 47 matched on 2026-08-21
NEULANDLAB matches 12 of the 47 scans today, across 6 different kinds of evidence. Three or more independent families agreeing is uncommon — it is the same test the shortlist on every page uses.
NEULANDLAB trades at 60× trailing earnings, below its median of 67× over this window — 11% less expensive than usual. The band runs from the 5th to the 95th percentile, so single-day spikes do not set the edges.
This window is short by the standards of valuation history — it begins where four quarters of filed earnings first exist. A stock can look cheap against two years and expensive against ten.
Other filing filings were typically -0.08pt vs the market over the next 5 sessions (n=12,093) · M&A filings were typically +0.23pt vs the market over the next 5 sessions (n=981) · Analyst call filings were typically +0.14pt vs the market over the next 5 sessions (n=3,352)
The business
from the company’s filed results
Everything below is taken from the company’s own quarterly filing with the exchange — the XBRL document it submitted, not a vendor’s summary of it. Figures in rupees crore.
RevenueNet profit, drawn inside its revenue barNet margin, own scale belowrupees crore, per quarter as filed. Revenue bars start at zero.
Going for it
revenue grew 119% against the same quarter a year earlier
profit rose 962% year on year
Going against it
net margin narrowed from 27.4% to 23.0%
Quarter-by-quarter numbers, as filed
Quarter
Revenue
Profit before tax
Net profit
EPS
Net margin
Q1 FY27
2026-06-30 · consolidated
642
198
148
115.10
23.0%
Q4 FY26
2026-03-31 · consolidated
776
287
213
165.76
27.4%
Q3 FY26
2025-12-31 · consolidated
440
54
41
31.62
9.2%
Q2 FY26
2025-09-30 · consolidated
514
129
97
75.49
18.8%
Q1 FY26
2025-06-30 · consolidated
293
18
14
10.83
4.7%
Q4 FY25
2025-03-31 · consolidated
328
39
28
21.67
8.5%
Quarterly filings are unaudited unless stated. Consolidated figures are used where the company files both. A single quarter is a noisy thing — the trend across the column is worth more than the top row.
Where the price stands
the same figures every scan on this site is computed from
Trend
Distance from the averages traders watch. Above all of them is a bull phase; below the 200-day is the line most investors use to say otherwise.
Versus 50-day average+18.6%
Versus 200-day average+45.6%
Below 52-week high-1.5%
Above 52-week low+101.7%
Momentum
How hard it has been pushed lately. Above 70 on RSI is stretched, below 30 is washed out — neither is a signal on its own.
RSI (14)73.0
Higher closes in last 52 of 5
Six-month return+76.47%
Risk and liquidity
What a position costs to hold and to exit. Position sizing starts with the daily swing, not with conviction.
Typical daily swing (ATR)3.93%
Volume versus 20-day0.3x
Median daily turnoverRs 119.7 cr
Peers
Healthcare · 67 classified companies
NEULANDLAB trades at 60.4× trailing earnings against an industry median of 44.0× across 64 other classified companies in its industry — more expensive than them, by 37%. A multiple is a statement about expectations, not about quality: cheap usually means the market expects less, and it is often right.